跳至主要内容
临床试验/JPRN-UMIN000047441
JPRN-UMIN000047441招募中Unknown

Real-world study on the efficacy of an adjunctive use of ipragliflozin for prevention of chronic kidney disease in patients with type 1 diabetes - Study on the efficacy of ipragliflozin for prevention of chronic kidney disease in type 1 diabetes

agasaki University0 个研究点目标入组 360 人开始时间: 2023年6月1日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with any of the following will be excluded: 1)Patients administered any SGLT2 inhibitors except for ipragliflozin during 24 months after index date. 2)Patients who administered ipragliflozin inadequately. 3) Patients who had previous history of malignancy within 5 years before enrollment or 2 years before/after index date. 4) Alcohol abuse or alcohol consumption > 20g per day 5) Patients who underwent hemodialysis within 5 years before enrollment or 2 years before/after index date. 6) Patients who had a history of pregnancy and/or breastfeeding within 5 years before enrollment or 2 years before/after index date. 7) Willingness not to provide informed consent. 8) Judged inappropriate to participate by the study investigator.

研究者

发起方
agasaki University

相似试验